Search results

  1. Spatially Resolved Tumor Microenvironment Predicts Treatment Outcomes in Relapsed/Refractory Hodgkin Lymphoma.

    … Predicts Treatment Outcomes in Relapsed/Refractory Hodgkin Lymphoma. Journal …

  2. Evaluation of clinical parameters and biomarkers in older, untreated mantle cell lymphoma patients receiving bendamustine-rituximab.

    … parameters and biomarkers in older, untreated mantle cell lymphoma patients receiving bendamustine-rituximab. …

  3. Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma: a phase Ib/II study.

    … rituximab or obinutuzumab in relapsed/refractory follicular lymphoma: a phase Ib/II study. …

  4. Diffuse large B-cell lymphoma.

    Diffuse large B-cell lymphoma. Journal …

  5. Phase II Trial of Nivolumab Plus Doxorubicin, Vinblastine, Dacarbazine as Frontline Therapy in Older Adults With Hodgkin Lymphoma.

    … as Frontline Therapy in Older Adults With Hodgkin Lymphoma. Journal …

  6. INCMOR0208-301 (LYTMOR0208)

    … in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma Drug Name …

  7. Treatment Patterns and Outcomes of Multiple Myeloma Patients Undergoing Second-Line Therapy: A Canadian Myeloma Research Group (CMRG) Analysis

    … Journal Clin Lymphoma Myeloma Leuk, 2025 …

  8. GO29781 (LYT29781)

    … Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia …

  9. (Acerta) ACE-LY-308

    … (ACP-196) in Subjects with Previously Untreated Mantle Cell Lymphoma Cancer …

  10. LY.18 (LYLY18)

    … for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Cancer …

Back to top